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What this thesis is about 
It has been known for many years that smoking is a risk factor for myocardial infarction (MI). However, 
whether there are gender differences in the effects of smoking, implying that smoking is more harmful 
in women than in men has been debated but not settled. In the first half of the twentieth century men 
were hugely overrepresented among smokers in the Western world. As the occurrence of diseases 
caused by smoking became increasingly apparent, fewer men started smoking and more men gave up 
the habit, but this was not the case to the same extent in women. Altogether, smoking habits have 
changed substantially in Western civilizations during the last 20 years and this has also occurred in 
Norway, where smoking became about equally common in men and women from the early 1990s. 
Therefore we hoped that the present project with recently collected data could contribute to an 
improved understanding of the relationship between smoking and patients admitted to hospital with MI 
in the two genders.  
The previous decade would be an appropriate period in which to collect clinical data that, could 
supplement the standard risk analysis of the smoking and gender issue based on population studies. 
Furthermore, the standardization of diagnosing and medical treatment of patients with MI represents a 
particularly suitable background for new investigations on this topic. Thus, the study explores 
information on patients diagnosed with MI in the hospital in Lillehammer. The data were entered 
consecutively into a database during the eight years from 1998 to 2005 and with further follow-up of 
mortality until September 2010.   
It is the intention that this study will provide some of knowledge about MI in relation to smoking and 
gender. It is possible that this information may enable health workers and policy makers to evaluate 
whether there is a need for different policies and preventive measures in men and women.  
  
6 
 
LIST OF PUBLICATIONS 
Study I 
Grundtvig M, Hagen TP, German M, Reikvam A. Sex-based differences in premature first myocardial 
infarction caused by smoking: twice as many years lost by women as by men. Eur J Cardiovasc Prev 
Rehabil 2009;16:174-9. 
Study II 
Grundtvig M, Hagen TP, Amrud ES, Reikvam A. Mortality after Myocardial Infarction: impact of gender 
and smoking status. Eur J Epidemiol 2011;26:385-393. 
Study III 
Grundtvig M, Hagen TP, Amrud ES, Reikvam A. Reduced life expectancy after myocardial infarction - 
smoking is more harmful for women than men. Submitted september  2011. 
  
7 
 
ABBREVIATIONS 
ECG Electro cardiogram 
HR Hazard ratio 
MI Myocardial Infarction 
NPR Norwegian Patient Registry 
TrI and TrT Cardiac troponin I and T 
 
  
8 
 
1. INTRODUCTION 
 
1.1 Epidemiology of myocardial infarction 
After the Second World War there was a substantial increase in mortality from MI in Norway and it 
reached a peak level in the early 1970s, a level that changed little until the middle of the 1980s, when 
a steep decrease began, which has since continued in the 1990s and the 2000s1, 2. Data on the 
incidence of MI has been lacking in Norway due to the lack of relevant registries and databases. 
However, since the 1990s some information has been obtained from the Norwegian Patient Registry 
(NPR) – a national patient administrative register. The number of hospital admissions for MI 
decreased by 18% between 1991 and 2000. The decline noted in Norway in the period before 20003 
was also found in other Scandinavian countries4-6. In the same period, varied results were reported in 
studies from the United States7-12 and no firm conclusions could be drawn from that country13.  
The number of MIs reported to the NPR increased by 33% between 2000 and 20023, 14 – an 
increase that was mainly due to the new definitions of MI15. A proportion of patients who previously 
were diagnosed with unstable angina pectoris, now received the diagnosis MI. However, also after 
2002 the number of MI admissions registered for MI in the NPR increased steadily and the NPR data 
in fact became increasingly unreliable. The increase was due to the fact that the NPR could not 
identify the patients on an individual level. A patient with MI after the introduction of coronary 
intervention as the preferred treatment for acute MI could be transferred between two or more 
hospitals for the same MI. Thus one MI could be counted two or more times. However, despite the 
increased number in the NPR, there are indications that the real incidence of MI observed in the 1990s 
continued the diminishing trend in the 2000s1 (Figure 1).  
On a population level in Norway, figures from the Cause of Death Registry (Statistics Norway) 
indicated a dramatic decline in mortality from MI, from a peak in 1987 to a much lower level in 2007 
(from 189 to 79.7 deaths per 100,000)1.  
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Figure 1. Trend in hospital admissions for acute myocardial infarction in Norway based on data from 
the NPR in 1991 and 1999 and estimated number of patients in 2004. 
*adjusted and estimated for troponin diagnostics; the difference between patients and admissions is 
explained in the text. 
Reproduced and adjusted with permission from Reikvam Å and Hagen T1. 
1.2 Risk factors for myocardial infarction 
Smoking, elevated serum cholesterol and high blood pressure have for many years been recognized 
as the classic risk factors for coronary artery disease16-31, but several other risk factors have been 
reported. The INTERHEART study32 identified another six modifiable risk factors, namely diabetes 
mellitus, physical activity, abdominal obesity, psychosocial stress, high risk diet, and moderate alcohol 
consumption, although the latter did not turn out to be of definite significance.  Dyslipidaemia and 
smoking were rated as the most important modifiable risk factors32. 
1.3 Gender and myocardial infarction  
Numerous studies have shown that in general, women get MI later in life than men; an average delay 
of the order of 6-10 years has been reported5, 33-36.  
The mortality from MI in Norway has been changing rapidly in both genders since 1970 but with a 
more marked fall for men (Figure 2). 
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Figure 2. Mortality from myocardial infarction in men and women over a 37-year period.  
Source: Folkehelseinstituttet. 
 
As a consequence the proportion of deaths from MI for men relative to women declined considerably 
in Norway from 1998 to 2005, from 1.35 to 1.2 and further to 1.1 in 200937. This means that the 
mortality from MI approached equality in the two genders.  
1.4 Smoking and myocardial infarction 
Smoking has an adverse effect on health38-42 and reduces life expectancy43-48. Some studies have 
reported the equal importance of the risk factor of smoking in the two genders, whereas others have 
found some differences, mainly that smoking was more deleterious in women49-61. 
Smoking cessation programs have been shown to be strongly associated with increased smoking 
cessation rates62, 63 and stopping smoking reduced the subsequent risk of MI64-67. Although the 
majority of patients try to stop smoking after an MI, one study found that about half were still smoking 
four years after the MI68. High smoking rates among women have caused an increased incidence of 
lung cancer and chronic obstructive pulmonary disease in the few past decades, and may also 
contribute  to a less favourable MI incidence trend in the female than in the male population69. 
Increased smoking rates in women, together with diminished smoking rates in men, can explain the MI 
trends. There is no doubt that smoking is detrimental to health, and it is possible that there are gender 
differences with regard to adverse effects. However, more research on the gender issue is needed. 
1.5 Epidemiology of smoking 
Smoking habits have changed in Europe in recent decades, with a fall for men but a much smaller 
change for women70. In Norway, 20% of the population aged 16-74 years now smoke71. Smoking has 
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been about equally prevalent in both genders since the early 1990s. The data are based on ‘Travel 
and holiday surveys’ that has been collected on a random selection of inhabitants four times per year71 
(Figure 3). 
    
 
   
Figure 3. Percentage of daily smokers according to gender in persons aged 16–74 in Norway from 
1973 to 2010. 
With permission 2011 © Statistisk sentralbyrå72. 
The mean age of onset of smoking among ever-smokers was equal in the genders for the birth cohorts 
from 1947 but three and two years later in women than in men for the birth cohorts 1927-1936 and 
1937-194673 (Figure 4). 
 
Figure 4. Mean age of onset of smoking among ever-smokers by gender and cohort. Pooled data 
2004 – 2006. 
With permission, 2012 Norwegian Institute for Alcohol and Drug Research (SIRUS)73. 
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In some age groups more women than men now smoke in Norway (Figure 5). The data are based on 
the same surveys as for Figure 371. 
 
Figure 5. Percentage of daily smokers according to gender and age in 2010. 
With permission, 2011 © Statistisk sentralbyrå74 
In summary, over the past few decades the differences between the genders with regard to 
incidence of MI, mortality from MI, and smoking habits have changed. Against this background it 
seems probable that extensive data from the last decade on hospitalized patients – encompassing a 
smoking history – may be a valuable source of information for risk assessment in the two genders. 
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2. AIMS OF THE THESIS 
2.1 General aims 
The aim of this thesis was to assess the relationship between smoking and MI with a particular focus 
on possible gender differences in a cohort of hospitalized patients with MI. 
2.2 Specific aims 
● To quantify the extent to which smoking causes the first MI to occur prematurely in women 
and men. 
●  To explore mortality after MI with special emphasis on the impact of gender and smoking 
status and, furthermore, to investigate possible interactions between these variables during short- and 
long-term follow-up.  
●  To investigate whether and to what extent gender and smoking affect years of life lost/gained 
in patients with MI compared with age- and gender-matched life expectancy in the general population. 
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3. METHODS 
3.1  Patient populations 
Every patient with a permanent address in Norway who was discharged with acute MI, alive or dead, 
from Innlandet Hospital Trust Lillehammer, irrespective of age and ward of treatment, was included in 
the study. The study included patients from the years 1998 to 2005. Patients who died in the 
emergency department were included. Patients treated in the ambulance for MI as instructed by 
hospital physicians on the basis of communication with the ambulance personnel and electronically 
transmitted ECGs, were also enrolled in the study. Neither patients who were declared dead before 
admission to the emergency department nor patients with an MI first treated in another hospital were 
included. There were a total of 2733 acute MIs in 2281 patients. 
There were no patients based on ambulance registration only. An MI was counted as a new event 
when the hospital had a first contact with the patient through admission to hospital or through the duty 
physician’s contact with the ambulance service by pre-hospital transmission of ECG. Patients first 
admitted to another hospital (and not by the instruction to the ambulance service of the hospital’s 
physician) were not counted. Care was undertaken to count an MI only once. Patients transferred 
between hospitals were only counted once for the same MI. 
Study I 
This first study included 1784 patients with a first MI, of whom 38% were women; mean ages of 
women and of men were 76.2±12.1 and 69.8±13.4 years, respectively. Among them, 26% had a 
history of angina pectoris. Significantly more women than men had diabetes mellitus, hypertension 
and history of angina pectoris. Women also had significantly higher serum cholesterol at admission. 
Current smokers and ex-smokers constituted 60.8% of the patients. 
During work with the database over the next year it was found that 32 patients (1.2%) in the sample 
(2733) had been erroneously classified, either because they were foreigners, had had a previous MI, 
or the database entries were duplicates. The dataset (the first paper) was re-examined based on the 
adjusted sample but the results were similar and not significantly different from those first calculated. 
Study II 
Based on the index stay, 2281 patients were included of whom 1752 patients had suffered their first 
MI. Of these 2281 patients, 36.8% were women, and the mean ages for women and men were 76.0 
and 70.2 years, respectively. 
Study III 
The patients were the same as in Study II, but the analyses were based on the last indexed MI for 
each patient, that is to say the MI last indexed in the inclusion period from 1998 to 2005. There were 
738 patients with a previous MI. Of the female and male patients, 57.1% and 27.5% respectively had 
never smoked of the last indexed MI.  
Years of life lost/gained were calculated as the age at death minus the life expectancy by gender 
groups for each county based on age similar to the patient’s age at the last indexed MI.  
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3.2 Definitions of myocardial infarction 
3.2.1 Definition used in the hospital between 1st January 1998 and 31st December 2000 
MI was diagnosed according to World Health Organization criteria75. This definition is summarized in 
Norwegian in Hjerteforum76.  
Two out of three of the following criteria had to be present:  
1. Retrosternal pain which may radiate to the neck, arms, or abdomen independent of respiration 
with a duration at least 20 minutes with no or transient effect of nitroglycerine. Accompanying 
symptoms may be nausea, vomiting, cold sweat, anxiety and dyspnoea or syncope/cardiac 
arrest. 
2. ST segment elevation in one or more leads. Negative T wave development. After a few hours 
up to 1-3 days, development of Q waves with transmural infarction. New left (or right) bundle 
branch block, together with typical clinical signs. 
3. Serum creatine kinase above 200 U/l for men and 150 U/l for women. Serum creatine kinase 
MB fraction higher than 10 μg/l. 
For the diagnosis it was usually required to have a doubling or decrease to half of the initial creatine 
kinase value, depending on the timing of blood sampling, to get a positive result. The hospital 
analysed troponin I from the end of 1998 as described in the next paragraph, but the result was only 
used as a tool to exclude MI as a cause of the symptoms of the patient until 1st January 2001. With a 
normal troponin I level, MI was excluded. 
3.2.2 The definition of myocardial infarction as stated by the European Society of Cardiology15 was 
used in the hospital from 1st January 2001 
Criteria for acute, evolving or recent MI 
Either one of the following criteria satisfied the diagnosis for an acute, evolving or recent MI: 
(I) Typical rise and gradual fall in cardiac troponin I (TrI). The following are biochemical indicators 
for detecting myocardial necrosis:  
(1) Maximal concentration of  TrI exceeding the decision limit (99th percentile of the values for a 
reference control group) on at least one occasion during the first 24 h after the index clinical 
event, with at least one of the following: 
(a) ischemic symptoms; 
(b) development of pathologic Q waves on the ECG; 
(c) ECG changes indicative of ischemia (ST segment elevation or depression) 
(II) Pathologic findings of an acute MI. 
Criteria for established MI 
Any one of the following criteria satisfies the diagnosis for established MI: 
(1) Development of new pathologic Q waves on serial ECGs. The patient may or may not 
remember previous symptoms. Biochemical markers of myocardial necrosis may have normalized, 
depending on the length of time that has passed since the infarct developed. 
(2) Pathologic findings of a healed or healing MI. 
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With the introduction of the troponins many manufacturers produced various biochemical kits with 
different reference values. The kits for TrI had large variations and different reference values 
depending on the manufacturers of the kits, and there was no uniform definition of limits for the 
diagnosis of MI. It was even more difficult to get reliable reference values because for example “Dade 
Böhring” had three different platforms for the protein analysis: Stratus® CS   -   Dimension®   -   Opus®. 
The European Society of Cardiology/American College of Cardiology/American Heart Association had 
no recommendation for cardiac TrI assay performance versus standards for cardiac marker testing 
soon after the release of the new definitions. The guidelines stated that at least one value should be 
above the 99.0th percentile of normal which was 0.07 ng/ml for Stratus and Dimension. It was 
recommended that the imprecision should have less than 10% of the coefficient of variation at the risk 
stratification cut-off of the 99th percentile. The laboratory in Innlandet Hospital Trust Lillehammer used 
a kit from the end of 1998 from Abbot Laboratories AS with a cut-off value consistent with MI for TrI of 
1.0 μg/l and a new kit from the same manufacturer from 22nd August 2002 with a cut-off value of 0.14 
μg/l. The problem with the precision (coefficient of variation) for all troponin kits is visualized in Figure 
6 for one kit used for analysing TrI. 
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Figure 6. Low end precision of troponin I against total % precision (CV). 
CV = coefficient of variation. Ng/ml=μg/l. cTnI=cardiac troponin I. 
Very small infarcts can be found by use of more sensitive markers of myocardial necrosis, which are 
TrI and TrT, and thus infarcts of less than 1 g of tissue could be discovered. With the introduction of 
the troponins physicians were able to identify patients with a significantly increased risk of further 
adverse events and death77-80. The use of troponins for the definition of MI identified more definite MIs 
than the number obtained using the previous World Health Organization criteria. For example, 83% 
more infarcts in a Finnish study81, 26% more in an unselected British cohort82 and 58% more in an 
English hospital83. There were increased proportions of females with the new criteria for MI. 
3.3  Choice of independent variables 
The three factors of smoking, serum cholesterol and blood pressure were the classic factors for 
coronary artery disease at the start of the database16-31.  
It was also known that diabetes mellitus was an important risk factor18, 84-88.  
A high level of social support, and living alone were known to impact on the risk of outcome in MI89-
92. Social status was therefore included.   
Stroke had been shown to be an important predictor of in-hospital mortality93 and peripheral 
vascular disease was a predictor of prognosis after MI discharge94. Since it was easy to obtain a 
history of stroke but more difficult to obtain information on peripheral vascular diseases, only the 
former variable was included. 
The presence of heart failure had been shown to be an independent risk factor for death in 
myocardial infarction95 as had necessary use of diuretics96, 97. Both the clinical parameter of heart 
failure and the use of diuretics in hospital and at discharge were therefore included.  
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Prescription of lipid modulating agents had been shown to be efficacious in primary and secondary 
prevention98, 99, and with an effect also seen in elderly individuals100-103. 
Use of adrenergic beta-antagonists (beta blockers) has been established treatments during and 
after MI104-109. In-hospital use of both a fibrinolytic agent (streptokinase) and aspirin had been found to 
reduce the 30 day-mortality in a study with a 2x2 factorial design (ISIS2)110. For both drugs, the effects 
were independent and additive and this was a breakthrough in establishing the validity of using aspirin 
in MI.  
The use of intravenous nitrate had been shown to reduce the mortality in a pooled analysis of six 
trials111 and this drug was therefore included.  
For in-hospital treatment and secondary prevention after MI, use of some beta-blockers106, 109, 112-115 
as well as use of angiotensin-converting enzyme inhibitors had been shown to improve survival, 
especially in patients with impaired myocardial function84, 113, 116-118.  
The use of digitalis during and after MI may be a marker of heart failure, but there was some 
uncertainty about whether it could reduce major cardiovascular outcomes119-126. The use of digitalis 
was therefore chosen as an independent variable. 
3.4 Microsoft Access database 
By the use of standard data collection forms, information on history, presenting features and treatment 
received was acquired.  
The database was programmed in Microsoft Access 1997. Re-programming was undertaken by 
Morten Grundtvig because it was necessary to enter new parameters and new choices for existing 
parameters in newer versions. The database contained one administrative page and one MI page with 
automatic generation of unique MI IDs when new MIs were entered. The IDs were linked to date of 
birth and the personal 5-digit number. The database was accessible through most computers used by 
doctors in the medical department and by nurses in the cardiology section. 
The registered parameters were the following: age; sex; family history; social status; working 
status; smoking status; history of treatment for hypertension; cholesterol value on admission; history of 
non-insulin and insulin-dependent diabetes mellitus; history of angina pectoris and previous 
myocardial infarction; history of stroke, deep venous thrombosis and pulmonary embolus; time from 
onset of symptoms to treatment; biochemical markers related to myocardial infarction; previous, in-
hospital and discharge heart medications; treatment for heart failure in hospital; time of death. The 
information was written on case report forms (CRF) as soon as a patient was diagnosed with MI, and 
the CRF was kept with the patient’s chart until discharge. The CRF was sent to the Coronary Care 
Unit where nurses typed the data into the registry. Dedicated nurses and Morten Grundtvig checked 
the database for missing values every month. 
3.5 The patient administrative system DIPS 
DIPS (Distribuert Informasjons og Pasientdatasystem i Sykehus) is the patient administrative 
system. It is based on modern technology: Microsoft Visual Studio, Oracle database and Borland 
Delphi programming and contains a number of components, including:  Direct Oracle Access, from 
Allround Automations, Wptools, from Julian Ziersch Software, Quantum Express, from Developer 
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Express Inc., Reportbuilder, from Digital Metaphors Corporation and ImageLib Corporate Suite, from 
SkyLine Tools. The version used during follow-up was DIPS 4.2.2.2 Build 003. DIPS was available 
with complete electronic information from January 1, 1998 of patient records – except the handwritten 
temperature/drug charts, which were only available in paper format. The database allows listing of 
patients with specified diagnostic numbers from ICD 9 and 10 according to time intervals. The system 
was updated online every fourteen days, registering deaths and dates of death from the Norwegian 
Death Registry administered by Statistics Norway. Report D737 allows identification, within a specified 
period, of every deceased person who had been in contact with the hospital at any time. This file was 
merged with our database using the official 11-digit personal number to identify deaths of patients. 
3.6 Statistics 
For Study I statistical analyses were performed with SAS, version 9.1 (Cary, North Carolina, USA).  
For study II statistical analyses were performed with Statistical Package for Social Sciences, 
PASW Statistics, version 18.0.2 (SPSS Inc. Chicago, Illinois) and verified by SAS, version 9.1 (SAS 
Institute Inc., Cary, NC, USA). 
For study III, statistical analyses were performed with IBM SPSS Statistics Version 19. The initial 
analyses for the structural equation modelling with Amos 19.0.0 (Build 1376) and the final analysis of 
this analysis was done using SAS version 9.2 (Proc Calis and Proc Reg; SAS Institute Inc., Cary, NC, 
USA). 
Risk factors other than the variables describing age, time and cholesterol levels were coded as 
categorical variables, with reference units (no events) given the value of zero. The male gender and 
living alone were coded zero. Bivariate comparisons for categorical variables were made by Pearson’s 
Chi-squared tests. Other variables were described by mean and standard deviation or mean and 
standard error, and comparisons between groups were made by Student t-tests within a general linear 
method (GLM) procedure.  
In Study I the association between risk factors and age at the first MI was analysed by multivariate 
regression within a general linear model. Explicit tests of the gender differences in the effects of 
smoking on age at first MI after control for relevant confounders were performed within a model 
including interaction terms between genders and smoking status (i.e. gender × ex-smoker and gender 
× current smoker).  
Study II used logistic regression by the forward Wald method for analysing the effects on mortality 
by possible confounders; smoking history and gender, including the interaction terms between 
genders and smoking status were entered at the last step.  
For the analyses of the effects of smoking history and gender differences on death after discharge, 
Cox regression analysis by the forward Wald method was used, including possible confounding 
variables. The same interaction terms between sexes and smoking status were used. 
In study III the actual age at death was subtracted from the projected age of death at the time of 
the MI – based on age- and gender-matched life expectancy in the general population – to yield year 
of life lost/gained. In bivariate analyses Student’s t-tests were used to determine differences between 
the genders with regard to years of life lost.  
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Years of life lost/gained was used as a dependent variable in multivariate analyses using structural 
equation modelling to determine the relative importance of risk factors among the patients. 
3.7      Formal requirements 
The study has been approved by the Privacy Ombudsman for Research, Oslo University Hospital, 
division Ullevaal, Oslo. The investigation complies with the principles outlined in the Declaration of 
Helsinki. 
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4. SUMMARY OF RESULTS 
4.1 Study 1. Investigation of how smoking affects age of onset of first MI in women and men 
Unadjusted mean ages at first MI were 76.2 years for women and 69.8 years for men, a difference of 
6.4 years (P < 0.001). Mean age within the various groups was: women non-smokers, 80.7 years, 
women smokers, 66.2 years – a difference of 14.4 years (P < 0.001); men non-smokers 72.2 years, 
men smokers, 63.9 years – a difference of 8.3 years (P < 0.001).  
After adjustment for risk factors (hypertension, cholesterol levels, diabetes) and patient 
characteristics (history of angina, history of stroke) 13.7 years of the age difference in women were 
attributed to smoking; the corresponding figure in men was 6.2 years (P<0.001).  
4.2 Study 2. The impact of smoking and gender on the mortality after MI 
The mean age for women at admission was 5.8 years higher than for men (76.0 vs. 70.2 years) and 
women were less likely to have been smokers. In-hospital mortality for the first MI was 8.9% for men 
and 13.3% for women, and total mortality levels for all indexed MI after seven years were 47% for men 
and 61% for women. Using Cox regression analysis, with all indexed MIs included, the after-discharge 
mortality for women was significantly lower than for men (hazard ratio 0.82; 95% confidence interval 
0.70–0.96; p = 0.015). Compared with non-smokers, patients who were smokers on admission had 
significantly increased seven-year mortality after discharge (hazard ratio 1.30; 95% confidence interval 
1.03–1.63; p = 0.002).   
A study of the cause of death was undertaken by randomly examining a selection127 of 20% of the 
patients discharged alive (N=183) after the last indexed MI; 71.6% died from definite or highly 
probable cardiovascular disease, 18.6% of other causes, and 9.8% of unknown causes. Similarly, a 
10% random sample of patients who died in-hospital during the index MI showed that only 1 of 34 
patients died of other causes than cardiovascular disease. Therefore, an estimated 85% of all those 
who died (in-hospital and after discharge) of the total sample (N=1259) died from cardiovascular 
diseases and 15% from other causes. 
4.3 Study 3. Investigation of how smoking affects years of life lost/gained after MI in women and 
men compared with age- and gender-matched groups in the general population 
During follow-up, it was found that more than 55 % of the patients had died. Bivariate analyses 
showed that both female and male non-smokers lost 5.4 years of life, whereas smoking women and 
men lost 11.6 years and 9.7 years (p=0.07), respectively; corresponding figures for ex-smokers were 
7.8 years and 6.0 years (p<0.001). In multivariate analyses, years of life lost were strongly related to 
age at the MI and significantly related to the quadratic term of age. Examples of years of life lost 
versus age at myocardial infarction are visualized in figure 7. 
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Panel A    Panel B      
 
Figure 7. Years of life lost versus age at myocardial infarction for female ex-smokers and current 
smokers (panel A) and for male ex-smokers and current smokers (panel B).  
By use of structural modelling equation it was found that figures for years of life lost were similar in 
non-smoking women and men. Smoking men lost 4.2 years more than non-smoking men. Female ex-
smokers and current smokers lost 1.8 and 1.9 years more than the corresponding groups of men.  
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5. Methodological considerations 
5.1 Patients 
The patients examined were those with a permanent address within the hospital’s catchment area, 
and people on holiday or business trips with permanent addresses in other parts of Norway. Patients 
who were admitted to other hospitals when staying outside the catchment area of Innlandet Hospital 
Trust Lillehammer, were not included. Exports and imports of patients have not been studied. Because 
Gudbrandsdalen is a popular valley to visit for holidays there may have been more imports of patients 
than exports. However, only 6.4% of the patients had a permanent address outside the ordinary 
catchment area of the hospital, indicating that the vast majority of the patients resided within the 
catchment area.  
About 80% of the population using the hospital in Lillehammer for acute admission lived further 
away than 15 km.  In this respect the hospital compares to other populations in Norway. However, 
more than 20% of the population had to travel further than 115 km, and a small proportion lived more 
than 200 km away from this hospital, implying very long transport distances. In fact, these distances 
are comparable to few other areas in Norway except the counties of Northern Norway.  
Only slightly more people were daily smokers in the county Oppland (24 %) than in the whole 
country (22%) in the 5-year period 2005-2009, and smoking status was therefore representative of 
Norway as a whole128. Death rates from ischemic heart disease have been somewhat higher in 
Oppland than for the average in Norway; the death rates per 100,000 in 2003 for men were 201 vs. 
179 for Norway as a whole, while the corresponding figures for women were 118 vs. 85129. This means 
that our study patients may have had more pronounced risk factors for ischemic heart disease than 
the average Norwegian population.  
The study is only valid for patients with MI who reached hospital alive.  Some individuals might 
suffer an MI without being transferred to hospital or may die before reaching hospital. The possibility 
that smoking, age or gender influence the chance of being admitted to hospital with MI could be 
considered.  
Undoubtedly, patients with recognized MI without contact with hospital services constitute a minor 
proportion of the total number of patients with MI. It is possible that a few patients in nursing homes 
are treated on location, without admission to hospital, because they have other advanced diseases 
(e.g. advanced cancer or dementia). This situation would in any case apply to the oldest part of the MI 
population and would slightly influence the age of a first MI and years of life lost. The literature does 
not give any indication that men and women are differentially admitted to hospital according to patient 
or physician choices.  
However, there are a fairly large number of patients with unrecognized MI during the event. In an 
evaluation of the Framingham data these accounted for 25% of the MIs, and almost half of those were 
“silent”, with a higher incidence in patients with diabetes mellitus and in the elderly130. The proportion 
of all infarcts that were unrecognized was higher in women and in older men; 30% of the unrecognized 
MIs in men were <55 years of age and 60% of the unrecognized MIs in women were < 65 years of 
age. Therefore, if one tries to make calculations that include unrecognized MIs in a total MI equation, it 
24 
 
cannot be ruled out that age at first MI could differ somewhat from our results and that findings related 
to gender could also differ. 
The proportion of patients with MI who dies out of hospital is substantial131. In a study from 
Sweden132 it was estimated that three times as many individuals with supposed MI (sudden deaths 
included), including first and later MIs, died out of hospital compared to those who died in hospital, and 
that these patients constituted one third of the total MI population. The female gender has been 
associated with lower risk of out of hospital death132, 133 (odds ratio 0.85, 95% confidence interval 0.83-
0.87132). Persons aged 35 – 54 years constituted 17.4% of out of hospital deaths related to coronary 
heart disease. This means that the major proportion of out of hospital deaths occur in people of older 
age. On average they were  two years younger than hospitalized patients who died within 28 days of 
the MI event132. It is unlikely that inclusion of the out of hospital MI deaths in our total MI material 
would significantly change the relative contribution of the genders with regard to the age at the first MI.  
 Another study reported that the number of individuals who died from MI outside hospital was four 
times higher than the number of MI deaths in hospital134. The studies referred to132, 134 included 
sudden deaths in patients with established coronary artery disease and previous MI, and these deaths 
are very often caused by electrical events or other cardiovascular diseases and are not related to a 
new MI.  
We are not aware of any studies showing differential hospital admission for smoking versus non-
smoking individuals with MI.  
Based on the above-mentioned considerations it cannot be ruled out that the inclusion of 
unrecognized MIs in the MI population might impact on the age of occurrence of the first MI and years 
of life lost, but if so, probably to a minor extent. Definite documentation of any impact can only be 
obtained through rather complicated prospective epidemiological studies. However, our study was 
undertaken to analyse patients admitted to hospital with MI. 
5.2 Statistical considerations 
5.2.1 The MI cohort 
In this study we examined a well-defined cohort (male and female with a defined disease) with a 
defined exposure (MI). Certain characteristics thought to be the most important at the time of 
designing the database were recorded. Based on the presence and level of the known characteristics 
(risk factors), covariate data were used to adjust for effect estimate (age at the time of the MI, mortality 
and years of life lost). This covariate effect can also be applied to disease-based sampling (case-
control studies) and to cross-classification of the source population135. In our study we did not have 
any case-controls as we were examining effects that would not apply to controls. The study had a 
cohort design including a high number of exposed cases with the potential to identify relatively small 
differences in effect estimates. It had the advantage that it was protected against bias because of its 
prospective design. The outcome was easy to measure (age at the time of the MI) and the effect 
estimate contained hard endpoints (mortality and years of life lost). One of the effect estimates had a 
long latency in many cases (death), and follow-up over many years required personal endurance from 
the investigator in order to obtain mortality statistics.  
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All the confounders chosen were potential risk factors for the disease studied (MI) and were 
associated with the exposure (MI) being examined. In studying MI and outcome as described, age was 
found to be the most important factor. The HR with respect to age had to be written with three decimal 
places because to obtain the actual hazard, the number had to be exponentially multiplied by itself 
according to the age in years. The other confounders were coded zero and one, which made it 
relevant to denote HR with only two decimal places for those variables. It is important to code gender 
as zero and one (and not 1 and 2); otherwise the interaction terms between smoking and gender 
would receive erroneous coding.  
In the design of the database, it was important to make no restrictions with regard to patient 
inclusion in order to avoid bias. Therefore, patients who died in the emergency department from MI 
were included. However, for practical reasons, some known confounding variables were not included 
in the database. These were: the number of cigarettes smoked daily, the amount of tobacco used for 
pipe smoking, amount of exercise, and information about dietary habits. In general, it is difficult to 
obtain reliable information on these parameters, and furthermore, the time available in our coronary 
care unit and medical wards did not allow us to obtain these data.  
To study the effect of gender and smoking on in-hospital mortality we included all the possible 
confounding variables in a multivariate analysis. The confounding variables regarding medications 
given in hospital could have introduced bias since a number of patients did not receive the medication, 
although medically indicated, as they died very early after admission and before the medication could 
be administered. Fifty-seven (2.5%) of the patients died on the day of admission and only 10.5% of 
those patients were given an intravenous beta blocker vs. 55.6% of those 99 patients discharged or 
transferred to invasive centres on the first day. The corresponding values for intravenous 
nitroglycerine were 15.8% vs. 57.6%, and for fibrinolytic therapy 31.6% vs. 60.6%. This made the HR 
for the medications more favourable than would appear in a randomized trial. One way to study this 
effect could be to conduct the analysis after excluding patients who died on the day of admission. 
However, such analyses were beyond the scope of this study. 
5.2.2 The risk factor of smoking 
The risk factor of smoking, in particular the length of the smoking periods in men and women, needs to 
be taken into consideration when the aim is to assess the patients` age at the first MI, which in fact 
was the aim in paper 1. The habit of smoking was taken up later by women than by men. A vast 
gender difference with regard to the proportions of smokers in the two genders existed in the 1970s 
(figure 2, paper 1), as was also the case in the preceding decades. For example, in the 1950s the 
proportion of male smokers in Norway was as high as 76-78% among men born 1915-1934136. 
Another peak occurred in women around 1970, with  the highest proportion of women  smokers (52%) 
observed in women born 1940-1949136. After the 1970s the gender gap decreased steadily and the 
proportions of smokers in the two genders became about the same in the 1990s137. In recent years the 
proportion of daily smokers in Norway has been below 20%, with little gender difference74. In 
summary, a first wave of increased smoking occurred in men, and a second wave followed in women 
some decades later. As a consequence of this development more men were first put at an increased 
risk of MI and later on the same occurred to women.  
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However, during all the decades referred to, the commencement of smoking followed a similar 
pattern in the two genders. Both men and women started to smoke as teenagers or young adults. 
Figure 4 shows this pattern, and it is evident that the average ages of smoking onset have remained 
about the same in a wide variety of birth cohorts73. Accordingly, most male and female smokers 
among our MI patients were likely to have had a long smoking history, that is to say an exposure to 
tobacco smoke in the range of four to six decades. Moreover, this means that the exposure times are 
comparable in the two genders; if anything, women started smoking at a slightly older age than men. 
These considerations of exposure times may indicate that smoking is more harmful in women, as the 
first MI occurred more prematurely in women smokers than in men smokers – an estimation based on 
comparisons with non-smoking MI patients in the two genders (paper 1). In fact, not taking into 
account the slightly later commencement of smoking in young women, compared to young men, could 
imply an underestimation – considered to be minor – of the deleterious effects in women.  
However, during the periods when smoking was on the rise among women, theoretically another 
pattern of smoking uptake and dissemination could have taken place. Women could have started to 
smoke later in life than men, for example at an age between 40 and 60. Then the exposure patterns 
would be different in the two genders, and our regression analyses would have been flawed. However, 
these deliberations are only theoretical as the smoking patterns are known, and are described above. 
In the assessment of the exposure dose of tobacco, others have reported that male smokers have 
always consumed more tobacco than female smokers in Norway138 (Internet reference in English139).  
If so, an increased risk and a worse outcome in men could be expected, which in fact is contrary to 
what we found. However, another relevant factor to this discussion is body weight. Women`s lower 
weight might mean that they do not tolerate as much tobacco smoke as men. Furthermore, biological 
gender differences, the importance of which has not been recognized, might have an impact.  
The main differences between our strictly clinical study and epidemiological population studies 
should be noted. In the latter studies the endpoints may differ from those we investigated. For 
example, one might be interested in examining the development with regard to the number of 
myocardial infarctions in the two genders in the society (population). Then the matter of differential 
exposure would be important. In a period when smoking among women is increasing, young women 
will contribute disproportionately to a “women smoker group” whereas a more balanced age 
composition will be found in a “men smoker group”. Consequently, under such circumstances 
analyses of the exposures and the contribution of smoking to the MI development in the two genders 
will become more complicated. Although such epidemiological studies by nature are quite different 
from the ones undertaken by us and presented in this thesis, we have encountered the view that the 
same type of bias as described for the epidemiological studies pertains to our study. However, we 
hope that our elaborations in this chapter will elucidate this matter and clear away fundamental 
misunderstandings.  
Also, another question arises – is it possible to define a denominator smoking population in the 
society, in men and women, from which the smoking MI patients are “recruited”? Before embarking on 
this discussion we need to be aware that the MI patients were included during an eight-year period, 
from 1998 to 2005 and that all hospitalized MI patients from this period were enrolled. This means that 
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the background smoking population, if it could be defined, had a complex composition, not least when 
taking into account that the risk factor of smoking – believed to be one of the strongest factors – on 
average had  exerted an effect for some decades.  
During our evaluations of this problem the view was put forward that MI cases may be considered 
stochastic events taking place at any time during the observation period of eight years, and 
accordingly the average age of the MI cases among smokers will reflect the average age of the 
smokers in the population. Correspondingly, the average age of MI cases among non-smokers will 
reflect the average age of the non-smokers in the population. Then it was asked whether the average 
ages of such putative denominator smoking and non-smoking populations could be recorded, and 
whether it would be possible in this way to obtain information about the relationships between the 
ages of possible denominator populations and the ages of the different MI groups. However, we 
consider this hypothesis to be too simplistic. In our opinion, in addition to some element of stochastic 
processes, specific external influences are more important, in particular exposure to tobacco smoke 
over many years. Thus, to record ages of potential denominator populations appears to be very 
complicated. Moreover, it is obvious that the average ages of the smoking men and women 
populations in the society are much lower – several decades lower – than the ages of the MI groups in 
our study. 
If we had examined the ages of men and women smoking populations at a certain time in the 
observation period (1998-2005) through a survey on smoking habits, we would have had to consider 
that smoking had already taken its toll, as some individuals in this period might have changed their 
smoking status after having suffered an MI, and more importantly, a proportion of the smokers would 
have died, many of them from cardiovascular diseases. In particular, this would pertain to older 
smokers who, besides the age disposition, also would have had smoking exposure for as long as 60-
70 years. Those suffering these outcomes would be so numerous that there would be an impact on 
the age of a potential smoking denominator population. Hence, background smoking populations in 
men and women, as well as the average ages of such populations, would in practice be hard to define, 
and in our opinion impossible to identify.  
With all the above-mentioned limitations the most sensible way to perform assessments of the age 
at the first MI is to use multivariate regression analyses, starting with the ages of the men and women 
MI patients, which in fact was what we did in the first analysis (article 1). A prerequisite for this 
approach is that the main factors imposing risks for MI were known in our study. We think we collected 
key information about this matter, which we could then use for the analyses. We are aware that the 
results of multivariate regression analyses should be interpreted with caution, among other reasons 
because some confounding factors might have remained unidentified. However, it was particularly 
reassuring that one of the risk factors considered to be very powerful in relation to MI - exposure to 
tobacco smoke - seemed to be well controlled for and comparable in the two genders. As described 
above, the smoking patterns were essentially similar in the two genders. Thus it is probable that the 
difference between the average age at the first MI in smoking women and non-smoking women was 
causally related to smoking, and the same will be true for smoking men versus non-smoking men. 
Moreover, this is a biologically plausible explanation.  
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The particularly early occurrence of MI in smoking women, 13.7 years earlier than in non-smoking 
women, compared to a corresponding difference of 6.2 years in men, suggests that smoking is more 
harmful in women than in men. Such gender differences are consistent with findings from studies of 
heart-disease registries140, 141 and they are also consistent with population-based study results23, 142. 
Admittedly, it may be problematic to make inferences about risk or life expectancy based on mean 
age of cases in different exposure groups such as gender or smoking when the mean ages of 
individuals in these different exposure groups in the population may differ. And this is possible for male 
and female smokers and non-smokers in the general population given differing time trends in smoking 
by gender. The lack of information about the denominator subgroups is a limitation of our study. 
The smoking history had three categories, ‘non-smoker’, ‘ex-smoker’ and ‘current smoker’. These 
categories were all coded zero and one. However, the current smokers had also smoked in the past 
(ex-smoker), but they did not fulfil the criterion of ‘ex-smoker’, namely to have stopped at least three 
months previously. The code for ‘current smoker’ was not weighted to adjust for this issue. Some 
might think weighting to be relevant. 
5.2.3  Multivariate regression analyses 
Mortality after discharge was analysed by Cox regression analyses. This is a robust statistical 
procedure in this study since the exact date of the MIs and all deaths were known for all the patients 
during follow-up. A missing parameter for only one of the confounding variables for an individual 
patient would exclude that patient from analysis. Therefore, it is very important to have complete data 
for all the confounding variables, as we had in this study, in order not to lose power that might be 
needed to detect differences using this statistic.  
In the regression analyses the forward Wald method was used as a first step and ‘enter’ (forced 
entry) was applied to all the variables significantly associated with mortality, adding gender and 
smoking history as a second step. Two parameters could not be analysed at the same time due to 
interactions between the two, namely diuretic use in hospital and the clinical judgment of heart failure. 
These two were closely interrelated and produced non-sensible results with respect to HR. Although in 
principle, all the known parameters should be tested, the investigator should not be precluded from 
applying common sense when using statistics. As a consequence, only the use of diuretics was 
applied.  
In the investigation of years of life lost as the dependent variable, an initial step was to use ordinary 
multivariate analyses. It became apparent that years of life lost was strongly related to age at MI which 
is logical because the younger one dies, the greater the loss of time to live. Using curve fitting for 
graphic presentation with regard to years of life lost versus age at MI, the best fit was quadratic. The 
significant parameters were age at MI, age square, insulin dependent diabetes mellitus, non-insulin 
diabetes mellitus and smoking history by gender (females losing more). History of hypertension and 
stroke were not significant risk factors in this model.  It was apparent that the various measured and 
unmeasured risk factors had a profound effect on years of life lost through age, since each factor had 
a direct effect on years of life lost and an indirect effect through age. The final effect could be a 
combination of these effects. The risk factors for age at admission were analysed in a separate 
multivariate analysis, and additional parameters that were significantly related to age at admission 
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were presence of angina pectoris (no previous MI) and previous MI. Creating models for elucidating 
these interactions was feasible by applying structural equation modelling (sometimes called path 
analysis), using Amos (Analysis of Moment Structures) in the IBM® SPSS® statistical package. 
Structural equation modelling is thought to be more accurate than standard multivariate statistics to 
confirm relationships between observed variables. An unusual constellation was the quadratic 
interaction term ‘age square’ which was significant in multivariate analyses in addition to age. It turned 
out that the handling of this quadratic term was not possible in Amos and the analysis was therefore 
made in the statistical package SAS. The final analysis was carried out using the ordinary least square 
method using SAS and verified by IBM® SPSS®. The final analysis consisted of two steps to get the 
sum of the direct and indirect effects on the years of life lost.  
5.3  Ethical considerations 
The database was established in 1998. It was introduced to be used as a quality control tool for the 
medical department in the treatment of patients with MI, but also as a research tool from which to 
publish.  At that time it was thought that it would not be in the interest of the patient to ask the patient 
for ‘informed consent’ to register data on mortality in the database, with the intent later to use the data 
in publications. In a stressful situation like an MI, this would in our opinion be entirely wrong and 
probably increase stress, worry and fear of dying. In MI studies undertaken before 1998, it was 
generally accepted not to ask for written informed consent. For example, this was the procedure used 
by the renowned ISIS (International Study of Infarct Survival) group in the randomized trials conducted 
during the 1980s, studies which also included many Norwegian patients143. Also, we found it unethical 
to retrospectively acquire informed consent from each individual at the start of this PhD-program in 
2009, as more than half of the patients were dead and it would be inappropriate to get consent from 
relatives. Among those still alive, many patients were very old and we considered it inappropriate to 
bring up this matter. 
The database contains a large number of patients, which makes it impossible for readers to identify 
individuals. Moreover, the database contains standard information and no data of a controversial 
nature. The Norwegian Data Inspectorate (Datatilsynet) is responsible for managing the Personal Data 
Act of 2000. However, the Inspectorate had appointed the Privacy Ombudsman for Research, Oslo 
University Hospital, Division Ullevaal, Oslo, to be responsible for research at Innlandet Hospital Trust, 
and thus also exempted the hospital from reporting to the Data Inspectorate. This is according to the 
’Regulation of Personal Information’ (Personopplysningsforskriftens) § 7-12, with reference to the law 
on ’Health Registries’ (Helseregisterlovens) § 36. Accordingly, the handling of data in this study 
complies with the requirements for the ‘Regulation of Personal Information’ as specified in the 
regulation § 7-27. The Privacy Ombudsman for Research, Oslo University Hospital, Division Ullevaal, 
Oslo, approved the study with a waiver to obtain informed consent from the patients. 
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6. DISCUSSION 
6.1  Age at the time of a first MI 
In this study, women without additional risk factors (smoking, diabetes mellitus, hypertension, stroke, 
angina pectoris and hypercholesterolemia) suffered MI 10 years later than men without the same risk 
factors144. A parallel to this observation is the finding that in patients with familial 
hypercholesterolemia, ischemic disease appeared nine years later in women than in men145. This 
could indicate that the risk factor of elevated serum cholesterol affects the genders differently, implying 
that some protection against ischemic diseases is present in these women. However, the female 
heavy smoking group in that study experienced onset of ischemic diseases at the same age as the 
corresponding male group145. These results are consistent with our finding of only a moderately higher 
age, 2.7 years, for the onset of the first MI in smoking women compared to smoking men. In another 
recent study the same offsetting of the age difference for the debut of the first MI was observed146. 
These findings are consistent with the fact that smoking is most harmful in women, and in particular 
evokes premature ischemic disease in the female gender, a finding that is in line with other studies147, 
148. 
The data are also consistent with those of population-based studies, which have shown a higher 
risk of smoking in women than in men in Norway, Denmark and Japan23, 149, 150. However, in some 
population studies, in particular the older ones, the gender difference in the effect of smoking was not 
found17, 151, 152. A recent large scale meta-analysis demonstrated a 25% increased risk in coronary 
heart disease in female smokers as compared with male smokers153. 
The INTERHEART study showed that the odds ratios for the effect of the risk factor smoking was 
stronger in women than in men32, and after adjusting for levels of risk factors, the gender difference in 
the probability of MI cases occurring before the age of 60 was reduced by more than 80%154. 
However, the median ages for the gender groups from western Europe in the INTERHEART study32 
were more than ten years lower than in our study of unselected patients, which makes it likely that a 
selection of patients with MI occurred in that study.  
In summary, the narrowing of the age gap between the genders for onset of ischemic heart disease 
in smokers is a strong indication that women are more affected by smoking than men. Our finding that 
a first MI occurred more prematurely in female than in male smokers144 was not unexpected, but the 
magnitude of the difference, implying that twice as many years were lost – that is years free of MI – by 
female as by male smokers, was greater than anticipated. 
It should be kept in mind that some major risk factors – cigarette smoking, elevated levels of 
cholesterol, high blood pressure, and diabetes – are present in the vast majority of patients with MI155. 
The INTERHEART study32 reported that more than 90% of all cases of MI worldwide were predicted 
by modifiable risk factors in both genders and at all ages. These factors were abnormal lipids, 
smoking, hypertension, diabetes, abdominal obesity, psychosocial factors, low consumption of fruit 
and vegetables, and lack of regular physical activity. Consumption of alcohol was not of definite 
significance. These findings suggest that approaches to prevention can be based on similar principles 
all over the world and thereby have the potential to prevent most premature cases of MI. However, 
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with regard to gender differences, premenopausal women seem to benefit from some protection, 
which is lost once menopause is reached156. 
6.2 In-hospital and short term mortality 
Mortality from MI should be studied with special attention to the characteristics of the study population. 
In particular, it is important to determine whether the sample is selected or unselected. Only in the 
latter case might it be representative of the population in a well-defined geographic area. Within the 
context of current-era clinical trials of ST-elevation MI and non ST-elevation MI, 30-day mortality rates 
of less than 2%-4% have been reported for selected patient populations157-159, whereas mortalities in 
the range of 10 to 12% has been found in less selected patient populations160. However, large 
observational studies on non-selected patients still report MI mortality rates of nearly 20%161, 162. The 
overall in-hospital mortality rates in our study on unselected patients were 14.3% for women and 
10.3% for men163, which compares favourably with other studies134, 162.  
The finding of higher in-hospital mortality in women in our study was confounded by risk factors, 
and hence gender was not found to be an independent determinant in multivariate analysis163. While 
some have reported a worse outcome for women than for men in the short term164-171, one study found 
lower in-hospital mortality in women172, but most others have found few differences between men and 
women after adjusting for age, despite differences in treatment173-189. Because the presence of 
angiographic coronary disease has been reported to be less190, equal191 and more183 in women 
compared to men, the diversity and poorer outcomes reported in women192, 193 are likely to be related 
to differently selected patient populations.  
Gender differences exist with regard to presentation and treatment in MI. Thrombolytics were less 
used in women than in men in our study163 as in other studies170, 194, but it is known that women with 
MI present less often with ST-segment elevation183, 195, 196. 
Some researchers have found that smokers who received thrombolytics had a better hospital 
survival than non-smokers receiving this therapy, but this was mainly confounded by age197, 198. 
Although there are differences in short-term mortality in subgroups of patients with acute MI, there is 
good evidence that men and women have an equal outcome and, furthermore, this is independent of 
smoking status, as we have found in our study of unselected patients163. The smoker’s paradox199-201, 
the fact that patients with a positive smoking history have lower mortality than non-smokers, emerges 
because of a different risk profile. After adjustments for confounders, primarily age, the difference in in-
hospital mortality between the smoking and non-smoking groups, was no longer present202. 
6.3  Long-term mortality and smoking 
Although no difference in mortality in relation to smoking history has been reported203, our finding of an 
enhanced risk of death for smokers of 30% is consistent with the findings by others67, 204, 205 of a 
diminished mortality risk for non-smokers, compared with smokers, in the range of one third to one 
half. One study reported that men and women who continued to smoke after an MI had 2.2 and 2.4 
times the age-adjusted mortality, respectively, of those who stopped smoking206. In a review paper   
quitters were found to have a reduced risk of death after an ischemic event of 36-38% compared with 
continuing smokers207, 208. A post-hoc analysis of 18,885 patients with coronary artery disease, 
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showed that the difference in absolute event rates between current and ex-smokers was 4.5%209. This 
is more than twice as large as the decrease in absolute event rates between high-dose and moderate-
dose statin therapy found in the IDEAL (1.7%) trial210 and TNT (2.2%) trial209. Our analyses are based 
on smoking status at the time of the indexed MI, and we did not have information on smoking habits 
for individual patients in the follow-up period. One study found that although most patients stopped 
smoking soon after an MI, and a quitting rate of 71% was recorded after three months, continued 
follow-up over four years showed that an increasing proportion of patients restarted smoking, with the 
result that less than half of the smokers remained ex-smokers211. This is consistent with our finding of 
relatively high smoking rates at the time of an MI among patients with a previous MI; 27% and 18.8% 
(men and women) 163, as compared to 38.7% and 22.5% in patients with their first MI. 
6.4 Long term mortality and gender 
Our one-year mortalities for patients discharged alive were 14.5% in men and 16.7% (data not shown 
in articles) in women which compares with 18% and 22% in a similar recent study of unselected 
patients from Sweden212. Our 3-year and 7-year mortalities were 32.3% and 47% for men and 41.7% 
and 61% in women. The 3-year mortalities are somewhat lower in our study than in the Swedish 
study212 (40.7% for men and 49.0% for women) even though they did not include patients who died 
before reaching the intensive care unit. Their patients were, however, somewhat older, men 2.5 years 
and women 3.2 years – which could account for the mortality differences. One possible explanation for 
the age difference may be the fact that a significantly lower proportion of the Swedish patients were 
smokers, 22% for men and 16% for women, versus 36.1% and 21.9%, respectively, in our study.  
With regard to gender differences after adjustment for confounders, most studies have reported 
similar mortalities for men and women after MI. In different investigations, the 10-month-213, one-year-
189, three-year-214,five-year-215 and 10-year-84, 203 mortalities were similar for men and women. Lower 
long-term mortality for women than for men has also been found172, 216, but these studies were 
selected with 80% women, and were undertaken in patients with chest pain with more than 50% of the 
patients being below 65 years of age. Our results from an unselected cohort showed a moderately 
lower long term mortality for women163, which is consistent with two recent reports212, 217. 
6.5 Years of life lost 
We found that the major factor affecting years of life lost in patients with MI, compared with age- and 
gender-matched groups in the general population, was current smoking. Male current smokers lost 4.2 
years more than male non-smokers. Almost all of this difference was an indirect effect, arising 
because the MI occurred prematurely, at an early age. Other important findings were that ex-smoking 
and current smoking women lost 1.8 and 1.9 years more than the corresponding categories of men. 
The effects have not been quantified in this way before, and show the particularly deleterious effect of 
smoking in women.  
There is an abundance of publications on mortality after MI and on the influence of different risk 
factors on this outcome, but to our knowledge the issue of years of life lost has not been reported. 
Some population-based studies on the effect of smoking, not specific to MI, have been carried out. An 
Icelandic study reported that the reduction of median life expectancy was greatest in "heavy" cigarette 
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smoking,13 years for men and 10 years for women57. A similar prospective study by Doll et al43 in 
British male doctors showed that, compared to those who had never smoked, total years of life lost by 
smokers was on average 10 years. In that study there were very few censored (not deceased at the 
time of analysis) persons as virtually all died during the 50-year follow-up. In the Icelandic study 47% 
of the men and 65% of the women were censored. This compares to 50% in men and 46% in women 
in our study. However, the designs of those studies were different from our study and they did not 
investigate the years of life lost for each individual patient. 
6.6  Limitations 
There is evidence that smokers have a worse prognosis after MI than non-smokers. We do not 
know the post-MI smoking status of the smokers in this cohort. As previously mentioned, our data 
indicate that only a moderate proportion of the smokers did quit after their MI163. This finding should be 
viewed in the light of the probability of a higher risk of a new MI for those who continued to smoke after 
their first MI compared to those who quit. This implies that the risk of death in the current smoker 
group after discharge might have been underestimated. 
In our study, some variables were unknown, such as the amount of tobacco used and possible 
exposure to passive smoking. Passive smoking has been shown to be important in relation to the 
occurrence of MI218.  
For studies 2 and 3, it was impossible to predict future events in those still alive. Ideally, risk 
factors, deaths, and years of life lost should be reported when almost all the patients are dead as was 
done in the study of Doll et al58. However, our study had a relatively long follow-up, during which more 
than 50% of the patients died, which is substantially higher than in most other studies173, 215, 217, 219, 220.  
Some risk factors reported to be important in population-based studies32 were not available. These 
are related to exercise, dietary habits, waist to hip ratio, and psychological stress, and are usually 
difficult to quantify. Serum cholesterol values obtained at admission for an MI are not very reliable 
because they will decline significantly within hours of the onset of the MI221 and because a proportion 
of patients have been treated with lipid-lowering medications for an unregistered period before the MI. 
For example, in our study 6.8% of the men and 8.1% of the women (difference p=0.363) had received 
cholesterol-reducing agents prior to admission, and for patients with a first MI who also had angina 
pectoris, 25% of the men and 16% of the women (p=0.019) had been given such drugs (data not 
reported in the articles). In addition, patients with chronic renal failure have worse outcome in acute 
coronary syndromes222, but parameters for renal function were not entered into our database. 
6.7 Future perspectives 
Men and women differ with regard to the presentation and responses to treatment of ischemic heart 
disease223. Also, as concerns susceptibility to the harmful effects of smoking, there seem to be gender 
differences. However, hormones obviously protect premenopausal women156 which is why young 
females usually avoid getting MI. By contrast, women seem to be become more susceptible after 
menopause. Health planners should implement programs to prevent young people from starting 
smoking and to encourage them to quit, and in this context should focus on the particularly harmful 
effects in women.  
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Further studies to explore and understand biologically the gender differences are warranted.  
Worldwide, more than five million people die each year because of tobacco smoke224. A major 
improvement in the prevention of MI has been achieved through legislation banning smoking in public 
areas. It has been estimated that this has caused a decline in MI occurrence in the order of 17%, and 
the improvement is still on the rise218. In Norway this legislation was introduced in 2004. It is promising 
that further restrictions on smoking, including legislation to protect children from exposure to tobacco 
smoke, are being debated. It is the expressed view of The Norwegian Medical Association that 
Norway should develop into a smoke-free society. Hopefully, in the future we will have an even more 
ambitious goal; the elimination of tobacco smoking all over the world. 
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7. CONCLUSIONS 
The present studies found the following answers to the posed scientific questions: 
1. To quantify the extent to which smoking causes first MI to occur prematurely in women and 
men hospitalized with MI. 
Smoking caused first MI to occur significantly more prematurely in women than in men, implying that 
twice as many years were lost – that is years free of MI – by women smokers as by men smokers. 
Smoking incurs a strong additional risk in women. 
2. To explore mortality after MI with special emphasis on the impact of gender and smoking 
status and, furthermore, investigate possible interactions between these variables during short- and 
long-term follow-up. 
Current smoking at the time of the indexed MI was associated with increased mortality after seven 
years follow-up. The smoking effect was independent of gender. Female gender was associated with a 
moderately lower risk of death during the same follow-up period. 
3. To investigate whether and to what extent gender and smoking affect years of life lost/gained 
in hospitalized patients with MI compared with age- and gender-matched life expectancy in the general 
population.  
MI caused a substantial number of years of life lost, with a heavier loss in current smokers than in ex-
smokers and non-smokers. The effect was predominantly an indirect one, related to the patients’ age 
at the event. Smoking reduced life expectancy more in women than in men, indicating that smoking is 
most detrimental in the female gender.  
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Background The aim was to investigate possible gender differences in the years of life lost 
after acute myocardial infarction (MI) and to explore how smoking affects life expectancy in the 
two genders. 
Design Clinical data were consecutively entered into a database and were analysed using 
structural equation modeling. 
Methods In the years 1998–2005, 2281 patients (36.8% women) who were discharged from or 
died in hospital following a diagnosis of MI were included. Survivors were followed for a mean of 
8 years. The age of death for each patient was subtracted from the average projected age of 
death for individuals in the general population with a similar age to the patient at the time of their 
MI. The effects of gender, smoking, and other risk factors on the years of life lost were 
analysed.  
Results During follow-up, 55 % of the patients died. Nonsmokers, exsmokers and current 
smokers lost 5.4, 6.4 and 10.3 years of life, respectively. Structural equation modeling showed 
that currently smoking men lost 4.2 more years more than did nonsmoking men (P<0.001), and 
this was mediated through more prematurely occurring MIs. Female current smokers lost 1.9 
years more than male current smokers and female exsmokers lost 1.8 years more than male 
exsmokers (both P<0.001).  
Conclusions MI caused a substantial number of years of life lost, with a heavier loss in current 
smokers than in exsmokers and nonsmokers. The effect was predominantly related to the 
patient’s age at the event. Smoking reduced life expectancy more in women than in men, 
indicating that smoking is most detrimental for the female gender. 
Word count: 262 
Keywords: smoking, myocardial infarction, sex, mortality, risk factors 
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The general life expectancy is high in Norway; in 2003 it was 77 years for men and 82 years for 
women and it has risen further since then.[1] The expected remaining years of life are 
calculated by Statistics Norway for every attained year of age, and according to the gender and 
county of habitation.[2] Calculations for the period 2000–2005 showed that men and women at 
40 years of age could expect to live to 76.6–79.7 and 81.8–84.0 years, respectively, depending 
on their county of habitation (recent update of the web-site shows the period 2006–2010).  
Myocardial infarction is a serious event entailing risk of immediate death or death in the 
subsequent years. Smoking is a prominent risk factor for cardiovascular diseases that might 
reduce life expectancy.[3] Whether there are gender differences in the effect of smoking – 
implying that smoking increases the risk of ischemic heart disease relatively more in women 
than in men – has been debated, but not settled.[4,5] In an investigation based on data acquired 
in hospital, we found that the first myocardial infarction occurred more prematurely in smoking 
women than in smoking men, 13.7 years and 6.2 years prematurely, respectively.[6] We also 
observed that smoking was associated with a gender-independent enhanced mortality during a 
7-year follow-up period after discharge, whereas female gender on its own was associated with 
a moderately lower risk of death.[7]  
Because of complex statistical relationships between risk factors, and the patient’s age at the 
time of a myocardial infarction, traditional regression analyses are not well suited for estimating 
the effects of smoking on years of life lost. This is because the patient’s age at the myocardial 
infarction is an intermediate variable that lies in the causal pathway between smoking and years 
of life lost. Therefore, smoking might have both direct effects on years of life lost, and indirect 
effects by causing myocardial infarction to occur prematurely. Structural equation modeling is a 
statistical method that allows investigation of relationships by quantifying effects along these 
pathways. To our knowledge, no former studies have used this statistical method to assess 
these relationships. Accordingly, the aim of the study was to investigate years of life lost after 
myocardial infarction and to analyse the effect of smoking history and other risk factors in both 
genders. 
Methods 
The study included non-selected patients with a permanent address in Norway who were 
discharged alive or dead from any department in the central hospital of the city of Lillehammer, 
Norway, with a diagnosis of acute myocardial infarction in the 8-year period 1998–2005 as 
described.[7] For those individuals with multiple myocardial infarctions occurring during the 
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inclusion period, only the last event was included in the analyses. The diagnosis of myocardial 
infarction before and after January 1, 2001 was based on the old[8] and the new[9] definitions, 
respectively.  
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We calculated the years of life lost for each individual (i) as: 
Years of life losti = ADi – LE a, g, c, 
where AD is the individual age at death and LE is the life expectancy calculated at the time of 
myocardial infarction by age (a), gender (g) and county (c). To reduce problems of stochastic variation, 
LE was calculated on the basis of averages from the years 2001–2005. Date of death was registered 
consecutively for patients dying in hospital and mortality dates were obtained on-line at regular 
intervals from the Norwegian Death Register, administered by Statistics Norway, for those discharged 
alive. Each subject’s date of birth was subtracted from the date of death to yield the age at death 
(ADi). Data on LE were provided by Statistics Norway.[2]  The number of years of life lost is a negative 
value (ADi <LE a, g, c) and the number of years gained is a positive value (ADi >LE a, g, c).  
Smoking habits were registered at hospitalization. If a smoking history was missing, the patient or 
his or her family was contacted by telephone to obtain the data. As a consequence, smoking history 
was known for all patients. The variable defining smoking had three categories: ‘current smoker’ if the 
patient smoked or had done so up until 3 months previously; ‘exsmoker’ if the patient was a former 
smoker and had stopped more than 3 months previously; and ‘nonsmoker’ if the patient had never 
smoked.  
Any history of hypertension, stroke or diabetes mellitus were self-reported during hospitalization 
and verified against relevant medical charts. 
Risk factors were coded as categorical variables with reference units (no events) given the value of 
zero. Male gender was coded zero and female one. Bivariate comparisons for categorical variables 
were made using Pearson’s Chi-squared test. Continuous variables are described by means and 
standard deviation. Years of life lost are described by means and standard error. Bivariate 
comparisons were carried out using Student’s t-tests.   
Years of life lost and age at myocardial infarction were used as endogenous variables in a 
multivariate analysis using structural equation modeling to calculate the direct and indirect effects of 
possible risk factors.[10] Covariates in addition to smoking habits were gender, diabetes mellitus with 
and without insulin treatment, hypertension, a history of stroke, previous myocardial infarction, or 
angina pectoris (with no previous myocardial infarction). Because of a decreasing effect of increasing 
age at the time of the myocardial infarction on the years of life lost found in initial analyses, the age at 
myocardial infarction was described using linear and quadratic terms. The quadratic term 'age at 
myocardial infarction squared' was included to capture the marginal decreasing effect of this variable. 
Additionally, we included interaction terms between gender and smoking status to capture possible 
differences in the effects of smoking between the two genders. In the final analysis of the direct effect 
of age at infarction, the estimate of years of life lost was calculated for the median age (75.3 years). 
These estimates are only valid for patients with an age of myocardial infarction between 40 and 100 
years. The basic pathways to years of life lost are shown in Figure 1. Indirect effects in a pathway can 
be found by multiplying directs effects. The total effect of a factor on years of life lost is the sum of the 
direct, indirect and possible interaction effects. Insignificant effects in initial analyses were eliminated 
by a backward procedure and not included in the final model and the calculation of total effects. 
Statistical analyses were performed using SAS version 9.2 (Proc Calis and Proc Reg; SAS Institute 
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Inc., Cary, NC, USA). Because our model was nonrecursive, ordinary least square and the more 
complex path model gave identical results and only results from the former are reported. All P values 
reported were from two-sided tests. 
The study was approved on April 19, 2010 by the Norwegian Privacy Ombudsman for Research 
with a waiver for informed consent. 
 
Results 
The study consisted of 2281 individual patients (36.8% women) who were discharged alive or dead 
with a diagnosis of any last myocardial infarction during the years 1998–2005. There were 1543 
patients with a first myocardial infarction (38.1% women). The ages of the patients at the myocardial 
infarction (men versus women) according to smoking categories were: nonsmokers 79.8±8.1 versus 
82.8±7.2, P<0.001; exsmokers 74.4±10.3 versus 74.8±10.0 years, P=0.67; current smokers 72.7±11.1 
versus 73.0±9.9, P=0.83. Characteristics and risk factors are given in Table 1. 
During the follow-up – a mean of 8 years among the survivors – a total of 55.2% (N=1259) of the 
patients died, 50.1% of the men and 64.0% of the women (P<0.001). With increasing age, increasing 
proportions of patients above 60 years died in both genders. For patients aged less than 60 years, 
11% of the men and 13% of the women died (difference P=0.70). Average ages at death were 
79.8±9.0 for men and 82.7±8.5 years for women (difference –2.9 years: P<0.001). Cardiovascular 
diseases were the cause of ~85% of the deaths; an estimate based on examination of random 
samples of the patients, 20% of those discharged alive and 10% of those who died in hospital. 
Compared with the general population, the years of life lost among patients with myocardial 
infarction were on average 6.8 years. Years of life lost were equally distributed between the genders in 
all risk categories examined using bivariate analysis, except for the groups exsmokers (P<0.001), 
current smokers (P=0.07) and patients with more than two risk factors (P=0.006), a group that showed 
a greater loss in women (Table 2). Exsmokers (N=426) had significantly more years of life lost than 
nonsmokers (N=555), 6.4 versus 5.4 years (P=0.001) and current smokers (N=278) a greater loss 
than exsmokers, 10.3 years versus 6.4 years (P<0.001). 
The results from the structural equation analyses are reported in Table 3 and the direct, indirect 
and total effects of the exogenous variables are calculated in Table 4. In general, the indirect effects of 
the age at myocardial infarction on the years of life lost were stronger than the direct effects. This is 
most clearly illustrated for smoking men described by the variable ‘current smoker’, where the direct 
effect from current smoking on years of life lost was insignificant whereas the indirect effect through 
age at myocardial infarction was –4.20. Female smokers lost 1.94 years in addition to the 4.20 years 
lost by smoking men: altogether 6.14 years were lost compared with nonsmoking men. 
Female nonsmokers (‘gender’) lost on average 1.63 years less than male nonsmokers through 
being older at the time of the myocardial infarction but lost 1.52 years more than men through a direct 
effect on loss of life with the result of having equal numbers of years of life lost as male nonsmokers. 
Thus, years of life lost after myocardial infarctions were similar for nonsmoking men and women. 
Male exsmokers lost 0.41 years of life more than male nonsmokers. Female exsmokers lost an 
additional 1.84 years, altogether 2.25 years more than male nonsmokers. 
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Patients with insulin-dependent diabetes mellitus lost 1.75 years more than patients without this 
disease through their age at myocardial infarction, and an additional 0.69 years as a direct effect on 
loss of life. The risk factor ‘non insulin-dependent diabetes mellitus’ was only marginally related to 
altered loss of life in this analysis (0.5 years) compared with patients without the disease. 
 
Discussion 
In our sample of patients with a mean age of 72.5 years (men 70.4, women 76.2) at the myocardial 
infarction, bivariate analysis showed that nonsmoking patients experienced an average reduction of 
5.4 years in their life expectancy. This is a substantial number of years lost, given that Norwegian men 
of 70 years of age have an average life expectancy of 12.8 years and women of 76 years of age can 
expect 11.2 years more.[2] Moreover, smokers had a particularly pronounced reduction of life 
expectancy, 10.3 years (both genders included) compared with the general population,  indicating a 
strong harmful influence from smoking. It is also of note that exsmokers had slightly more years of life 
lost than did nonsmokers. 
The structural equation model showed that the impact of smoking on years of life lost was not 
primarily a direct, but an indirect effect and came as a result of smoking causing the myocardial 
infarctions to occur prematurely. Furthermore, our findings support the notion that smoking, through 
this mechanism, is more deleterious in women than in men because female current smokers lost 1.9 
years in addition to the 4.2 years lost by male current smokers; moreover exsmoking women lost 1.8 
years more than exsmoking men. These results are in keeping with our previous finding of a more 
harmful effect of smoking in women by causing the first myocardial infarction to occur relatively more 
prematurely in women than in men.[6] The biological explanation for the gender differences might be 
that smoking women have a particularly enhanced risk of developing atherothrombosis in the coronary 
arteries, and this factor gives an accompanying increased risk of fatal cardiovascular events.  
Besides smoking, patients with insulin-dependent diabetes mellitus turned out to have a 
significantly shorter life expectancy than patients without this disease; this finding is consistent with 
other reports.[11,12]  
In general, smoking by itself and without any particular linkage to cardiovascular diseases is a 
strong risk factor for premature death. In a prospective population-based study, smoking was found to 
incur an average loss of 13 and 10 years – all causes of death included – in middle-aged men and 
women, respectively.[13] The British doctors’ study on men recorded smoking habits in each decade 
over the age of 50 and found that those who continued to smoke died on average about 10 years 
younger than lifelong nonsmokers.[14] A 10-year loss of life for smoking men was also reported in the 
Whitehall study.[3]  
Mortality from coronary disease has been declining in the Western world over the past decades, 
especially during the 1990s and 2000s, as shown in the USA,[15] Sweeden,[16] and Finland.[17] In all 
these studies and in the INTERHEART study,[18] smoking appeared as a prominent risk factor, which 
is consistent with our observations. 
Interestingly, the smoking cessation rates in Norway have been higher for men than for women 
during the past decades and at present the smoking rate is about 20% in both genders, down from 
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52% in men and 30% in women in 1973.[19] During the same era the mortality from myocardial 
infarction in the population has been declining more in men,[20] so this more pronounced mortality 
reduction might be linked to a particularly marked decline in smoking in the male population.  
A strong feature of our study was its unselected nature, as all patients hospitalized in the 
catchment area were included. It also contained extensive details about patient characteristics. 
Furthermore, we calculated the exact years of life lost/gained for each individual who died. This 
information enabled us to undertake multivariate analyses and provide information on how various 
factors contributed to years of life lost. We believe that our study is the first to undertake this kind of 
analysis.  
A limitation of this study is that our analyses were based on smoking status at the time of the 
myocardial infarction, and we did not have information on smoking habits for individual patients in the 
follow-up period. We assumed that a certain proportion of current smokers abandoned smoking after 
the myocardial infarction, whereas it is unlikely that nonsmokers started smoking. However, our data 
indicate that only a moderate proportion of the smokers did in fact quit. This is inferred from the 
observation of high smoking rates at the time of the myocardial infarctions among those with a 
previous episode; in fact, in both genders these smoking rates were about two thirds of the rates of 
patients with their first myocardial infarction(data not shown).[7] In any case, it is likely that a 
proportion of those categorized as smokers in our analyses would have quit after the myocardial 
infarction, and this might have underestimated the harmful effect of smoking and the risk of death 
among smokers. Therefore, the estimation of years of life lost among those patients who continued to 
smoke until their death most likely would have resulted in even more lost years. 
The patient’s place of habitation was registered as their address of residence at the last episode of 
myocardial infarction; previous places of residence were not taken into account. Thus, some patients 
could have been given an incorrect life expectancy because this differs somewhat between counties in 
Norway. However, this was not likely to cause a major error as most of these patients were 
pensioners, who rarely change their place of habitation. 
The calculation of years of life lost was based on an analysis of those who died (55.2%), with the 
proportion being highest in the oldest age groups. The actual years of life lost would increase if a high 
percentage of the younger patients still alive were to die within a few years. Conversely, if such 
patients would attain a near-normal expected lifespan, the overall years of life lost would not differ 
much from our estimates. However, there is no reliable method that can give predictions with regard to 
the lifespan of those still alive after the follow-up period. 
In conclusion, life expectancy after myocardial infarction was generally reduced, more so in 
smokers than in nonsmokers, and with the largest reduction in women with a positive smoking history. 
Years of life lost were primarily the result of an indirect effect, caused by an onset of infarction at an 
early age. 
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Fig. 1.  Illustration of Direct, Indirect and Interaction Effects for Gender and Current Smokers. 
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Fig. 2. Years of life lost versus the age at the last registered myocardial infarction in 1259 patients who 
died.  
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Table 1  
Baseline characteristics for patients hospitalized with acute myocardial infarction in the 8-year period 
from 1998.*  
Parameters Total Men Women Difference§ 
     P value 
Age (years±standard deviation) 72.5±12.6  70.4±12.7 76.2±11.5 –5.8 <0.001 
Age squared (years2±standard 
deviation) 
5421±1738 5119±1719 5938±1646 –819 <0.001 
 No. (%) No. (%) No. (%) %  
Gender 2281 (100) 1442 (63.2) 839 (36.8) 26.4 <0.001 
Nonsmoker 876 (38.4) 397 (27.5) 479 (57.1) –29.6 <0.001 
Exsmoker  728 (31.9) 544 (37.7) 184 (21.9) 15.8 <0.001 
Current smoker 677 (29.7) 501 (34.7) 176 (21.0) 13.7 <0.001 
Diabetes mellitus without insulin  224 (9.8)   128 (8.9)   96 (11.4) –2.5 0.05 
Diabetes mellitus with insulin  161 (7.1)     89 (6.2) 72 (8.6) –2.4 0.03 
Angina pectoris (no previous 
myocardial infarction) 
383 (16.8) 208 (14.4) 175 (20.9) –6.5 <0.001 
Previous myocardial infarction 738 (32.4)  487 (33.8)  251 (29.9) –1.4 0.06 
Hypertension  832 (36.5) 457 (31.7) 375 (44.7) –13.0 <0.001 
History of stroke  316 (13.9) 197 (13.7) 119 (14.2) –0.5 0.73 
* If a patient experienced more than one myocardial infarction in the 8-year period, only the last 
myocardial infarction was entered in the analyses.  
§ Differences were calculated as values for men minus values for women and p-values were 
calculated using the Chi-squared test for categorical variables and by Student’s t-test for age. 
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*during mean 8 years of follow-up in survivors. 
  
Table 2  
Number of hospital patients with acute myocardial infarction 
 Age groups (years)  
Gender  <40 40-<50 50-<60 60-<70 70-<80 80-<90 >90 Total 
Male – no. 13 92 224 291 456 326 40 1442 
% dead* 15.4 6.5 12.9 31.3 61.6 83.7 100 50.1 
Female – no. 6 16 68 122 256 314 57 839 
% dead* 0 18.8 13.2 36.9 67.2 80.6 96.5 64.0 
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* Shown are risk factor analysis for 1259 patients (men n=722 and women n=537) who died among 
2281 during a mean of 8 years of follow-up in survivors. Variables are listed as the mean and 
(standard error) in years.  
§ Differences were calculated as values for men minus values for women and P values were 
calculated using Student’s  t-test.  
† Risk factors: current smoker, exsmoker, hypertension, any form of diabetes mellitus and history of 
stroke. 
  
Table 3   
Years of life lost  among patients with a myocardial infarction in relation to life expectancy in the general 
population*  
         Difference§ 
Parameter Total Men  Women Years P value 
Gender –6.8 (0.2) –6.8 (0.2) –6.9 (0.3) 0.1 0.76 
Nonsmoker  –5.4 (0.2) –5.4 (0.3) –5.5 (0.3) 0.1 0.89 
Exsmoker  –6.4 (0.2) –6.0 (0.3) –7.8 (0.4) 1.9  <0.001 
Current smoker –10.3 (0.5) –9.7 (0.6) –11.6 (0.9) 1.8  0.07 
Diabetes mellitus without insulin  –6.8 (0.4) –6.4 (0.5) –7.2 (0.6) 0.8  0.34 
Diabetes mellitus with insulin  –8.4 (0.6) –7.7 (0.8) –9.2 (0.9) 1.6  0.17 
Hypertension  –6.8 (0.3) –7.1 (0.4) –6.6 (0.3) –0.6  0.25 
History of stroke  –6.2 (0.3) –6.1 (0.4) –6.5 (0.4) 0.4  0.49 
Risk factors†      
None –5.1 (0.4) –5.0 (0.6) –5.1 (0.5) 0.1  0.93 
One –7.0 (0.3) –7.1 (0.4) –6.9 (0.4) –0.2  0.75 
Two –7.2 (0.3) –7.1 (0.4) –7.4 (0.5) 0.3  0.63 
More than two –7.7 (0.5) –6.9 (0.5) –9.6 (0.9) 2.6  0.006 
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Table 4  
Final analysis of the structural equation model of the estimate of years of life lost in relation to risk* 
Variable 
Age at myocardial 
infarction 
 Age at myocardial 
infarction squared 
 
Years of life lost§ 
Estimate P value  Estimate P value Estimate P value 
Intercept 78.35 <0.001  6,212.74 <0.001  –6.44† <0.001 
Age at myocardial infarction — —  — —  2.28 <0.001 
Age at myocardial infarction squared — —  — —  –0.0116 <0.001 
Gender 3.69 <0.001  585.82 <0.001  –1.53 <0.001 
Exsmoker — —  — <0.001  –0.41 0.02 
Current smoker –6.70 <0.001  –956.79 <0.001  — — 
Exsmoker u gender –4.44 <0.001  –716.15 <0.001  — — 
Current smoker u gender –3.20 0.008  –540.81 0.003  –0.90 0.008 
Diabetes mellitus without insulin — —  — —  –0.51 0.03 
Diabetes mellitus with insulin –3.60 <0.001  –558.76 <0.001  –0.69 0.01 
Angina pectoris (no previous myocardial 
infarction) 2.24 <0.001 
 
340.77 <0.001 
 
— — 
Previous myocardial infarction 2.04 <0.001  295.95 <0.001  –0.52 0.001 
Adjusted R square  0.18   0.18   0.78 
* Shown are results for 1259 patients with a myocardial infarction who died among a total of 2281 
during a mean 8 years follow-up in survivors.  
§ The variables ‘history of hypertension’ and ‘history of stroke’ were not significantly associated with 
the years of life lost in the final analysis.  
† This estimate was calculated for the median age at myocardial infarction. 
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Table 5 
Years of Life Lost among Patients with a Myocardial Infarction through Direct and Indirect Effects*  
Parameter Direct effect 
Indirect effect 
through age at 
myocardial 
infarction 
Indirect effect 
through age at 
myocardial 
infarction square 
Total effect 
years of life 
lost 
Gender (male=0; female=1) –1.53   8.42 –6.80  0.10 
Ex-smoker –0.41   0.00   0.00 –0.41 
Current smoker  0.00 –15.29 11.09 –4.20 
Exsmoker u gender  0.00 –10.14   8.30 –1.84 
Current smoker u gender –0.90 –7.31  6.27 –1.94 
Diabetes mellitus without insulin –0.51   0.00  0.00 –0.51 
Diabetes mellitus with insulin –0.69 –8.23  6.48 –2.44 
Angina pectoris (no previous 
myocardial infarction)  0.00  5.12 –3.95  1.17 
Previous myocardial infarction –0.52  4.65 –3.43  0.70 
* Shown are data in years calculated from Table 4. The total effect is the sum of direct and indirect 
effects. 
 

